<DOC>
	<DOCNO>NCT01046266</DOCNO>
	<brief_summary>This open-label study ass pharmacodynamics , safety efficacy RO5083945 compare cetuximab patient head neck squamous cell carcinoma . Patients receive least 2 infusion either RO5083945 cetuximab . Anticipated time study treatment 3 month , target sample size &lt; 50 .</brief_summary>
	<brief_title>A Study Pharmacodynamics RO5083945 Patients With Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>adult patient , &gt; /=18 year age squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx carcinoma nasal cavity , paranasal sinus nasopharynx recurrent squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx know positivity HIV , hepatitis B and/or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>